Teleste Oyj
Teleste Corporation Stock Exchange Release 22 March 2021 at 9.00 am (EET)
Teleste Corporation’s conveyance of own shares based on the long-term incentive plan 2018
A total of 8 225 Teleste Corporation's treasury shares were conveyed without consideration to the key employees participating in the plan period 2018-2020 of Teleste long-term share-based incentive programme 2018 in accordance with the terms and conditions of the plan. More detailed information about the launch of the plan period and its terms and conditions is available in a stock exchange release published on 8 February 2018.
The decision on the directed share issue is based on the authorisation granted to the Board of Directors by the Annual General Meeting of Shareholders held on 22 April 2020.
After the share delivery on 19 March 2021, the company holds a total of 768 194 own shares.
TELESTE CORPORATION
The Board of Directors
ADDITIONAL INFORMATION:
SVP HR Tuomas Vanne, phone +358 2 2605 611
DISTRIBUTION:
Nasdaq Helsinki
Main Media
www.teleste.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
NTR Holding A/S9.1.2026 09:37:54 CET | Press release
Nasdaq Copenhagen A/S godkender afnotering af NTR Holding A/S’ B-aktier
Alveus Therapeutics Inc9.1.2026 09:13:19 CET | Pressemeddelelse
Alveus Therapeutics annoncerer serie A-financiering på 160 mio. USD til næste generations behandlinger mod fedme og stofskiftesygdomme
Yacht Club de Monaco9.1.2026 09:05:00 CET | Press release
At the Yacht Club de Monaco a year of transition and innovation begins
Onco3R Therapeutics BV9.1.2026 09:00:00 CET | Press release
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
Zealand Pharma9.1.2026 08:00:00 CET | Press release
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
